BNTCBenitec Biopharma Inc.vs its industry peers
A metric-by-metric comparison of Benitec Biopharma Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BNTC본 종목 | $389M#8 | — | 2.2x#3 | — | -100.0%#3 | -20.1%#3 | — | -25.7%#1 | — | — | -17.9%#3 | — |
| SPRY | $421M#1 | — | 33.7x#6 | 5.0x#2 | -5.5%#2 | -2241.8%#8 | -212.9%#2 | -1369.1%#8 | -177.6%#2 | — | -57.5%#7 | — |
| AVIR | $419M#2 | — | 2.1x#2 | 1.2x#1 | 622.5%#1 | 6.0%#1 | -51.5%#1 | -77.4%#4 | — | — | 72.3%#1 | — |
| GTBP | $410M#3 | 1.7x#1 | 114.8x#7 | — | — | -115.4%#7 | — | -794.5%#7 | — | — | -54.8%#6 | 0.1%#1 |
| LRMR | $408M#4 | — | 3.2x#4 | — | — | -105.5%#6 | — | -130.1%#5 | -350.3%#3 | — | -1.0%#2 | — |
| RZLT | $402M#5 | — | 3.4x#5 | — | — | -8.7%#2 | — | -63.7%#3 | -72.2%#1 | — | -44.1%#4 | — |
| TTRX | $395M#6 | — | 575.0x#8 | — | — | -80.6%#5 | — | -465.0%#6 | — | — | — | — |
| BBOT | $391M#7 | — | 1.2x#1 | — | — | -80.5%#4 | — | -41.5%#2 | — | — | -50.4%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-15.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice